Funding for this research was provided by:
National Cancer Institute (R01CA105304)
Article History
Received: 29 July 2020
Accepted: 13 September 2020
First Online: 20 September 2020
Compliance with ethical standards
:
: The authors declare the following conflict of interests: J.K.L, T.T., J.W., and M.D.S. are inventors of technology pertaining to AR N-terminal domain inhibitors, which was licensed by BC Cancer to ESSA Pharma Inc. M.D.S. owns equity in and is a Scientific Advisor for ESSA Pharma Inc. Their interests are reviewed and managed by BC Cancer in accordance with its research conflict of interest policy.